Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  Bloechl, Stefanie ^a   Beck, Roswitha ^a   Seidl, Christof ^a   Morgenstern, Alfred ^b   Schwaiger, Markus ^a   Senekowitsch Schmidtke, Reingard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BISMUTH 213; CARCINOEMBRYONIC ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; STOMACH CANCER; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; RATS; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 26444446027     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0017     Document Type: Conference Paper

References (25)

1. Handschuh G, Candidus S, Luber B, et al. Tumor-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion, and increase cellular motility. Oncogene 1999;18:4301-12.
2. Becker K-F, Kremmer E, Eulitz M, et al. Functional allelic loss detected at the protein level in archival human tumors using allele-specific E-cadherin monoclonal antibodies. J Pathol 2002;197:567-74.
3. 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional α- radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001;61:2804-8.
4. Miederer M, Seidl C, Beyer G-J, Charlton DE, et al. Comparison of the radiotoxicity of two α emitting immunoconjugates Terbium-149 and Bismuth-213 directed against a tumor-specific, Exon 9 deleted (d9) E-cadherin adhesion protein. Radiat Res 2003;159:612-20.
5. 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur Nucl Med Mol Imaging. In press 2005.
6. Brechbiel MW, Pippin CG, McMurry TJ, et al. An effective chelating agent for labeling of monoclonal antibody with Bi-212 for α-particle mediated radioimmuno-therapy. J Chem Soc Chem Commun 1991;1169-70.
7. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 1995;22:387-90.
8. Huber R, Seidl C, Schmid E, et al. Locoregional α- radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clin Cancer Res 2003;9:3922-8s.
9. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993;53:5815-21.
10. Apostolidis C, Carlos-Márquez R, Janssens W, Molinet R, Nikula T, Ouadi A. Cancer treatment using Bi-213 and Ac-225 in radioimmunotherapy. Nuclear News 2001;44:29-35.
11. Fukudome Y, Yanagihara K, Takeichi M, Ito F, Shibamoto S. Characterization of a mutant E-cadherin protein encoded by a mutant gene frequently seen in diffuse-type human gastric carcinoma. Int J Cancer 2000;88:579-83.
12. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med 1998;25:1341-51.
13. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted α-particle radiotherapy. Curr Pharm Des 2000;6:1433-55.
14. Imam SK. Advancements in cancer therapy with α-emitters: a review. Int J Radiat Oncol Biol Phys 2001;51:271-8.
15. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted Actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63:5084-90.
16. 211At-labeled monoclonal antibody Mov18. Anticancer Res 2000;20:459-62.
17. Allen BJ, Rizvi S, Li Y, Tian Z, Ranson M. In vitro and preclinical targeted α therapy for melanoma, breast, prostate and colorectal cancers. Oncology/Hematology 2001;39:139-46.
18. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-100.
19. 213Bi]-MAbTES-23. Eur J Cancer 2002;38:1278-87.
20. Nikula TK, McDevitt MR, Finn RD, et al. α-Emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity, and chemistry. J Nucl Med 1999;40:166-77.
21. Adams GP, Shaller CC, Chappell LL, et al. Delivery of the α-emitting radioisotope Bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol 2000;27:339-46.
22. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res 1999;59:2635-43.
23. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. Cancer Biother Radiopharm 2000;15:53.
24. 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm 2004;19:135-47.
25. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002;94:1332-48.